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Purpose: Intravenous (IV) zoledronic acid (ZA) is commonly used to delay skeletal   complications 
secondary to bone metastases. However, the time associated with ZA a  dministration may 
  represent a significant burden to healthcare providers and patients. This study assessed the time 
associated with IV ZA infusion in patients with bone metastases secondary to breast or prostate 
cancer (BC or PC) in the clinic setting.
Methods: Eligible BC or PC patients with bone metastases scheduled to receive IV ZA were 
observed at seven US-based oncology clinics. Trained observers recorded the time for preinfu-
sion tasks, ZA drug preparation, intravenous infusion, and follow-up activities.
Results: Data are reported for 39 patients (BC: 24; PC: 15). Mean administration time was 69 
(standard deviation [SD] 42) minutes for all patients combined, 72 (SD 47) minutes for BC, 
and 65 (SD 33) minutes for PC. Activity times were comparable between tumor types. Mean 
time for preinfusion tasks (eg, assessment of vital signs, blood draw) and ZA preparation were 
12 (SD 20) minutes and 2 (SD 1) minutes, respectively. Mean time required for intravenous 
infusion (ZA infusion and hydration, when provided) and follow-up activities were 54 (SD 31) 
minutes and 2 (SD 1) minutes, respectively.
Conclusion: Infusion time was the greatest time commitment associated with IV ZA admin-
istration, representing 78% of the total time on average. Time for preinfusion activities varied 
substantially. Overall, the mean time for ZA administration represents a notable time burden 
for healthcare providers and patients.
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Introduction
The diagnosis of bone metastases represents a sentinel event in the progression of solid 
tumors. The goal of treatment in patients with bone metastases is to prevent or delay 
skeletal complications, maintain functional independence, prevent or alleviate pain, 
and maintain health-related quality of life with limited burden to patients.1–3
The skeleton is the most common site for metastasis among patients with 
advanced cancer, resulting in loss of structural integrity of the bone and significant 
patient   morbidity.4 Bone metastases reduce weight-bearing capabilities of bone and 
frequently lead to skeletal complications such as pathologic fractures, spinal cord 
compression, and radiation or surgery to the bone,1 collectively referred to as skeletal-
related events (SREs).
Treatment options for bone metastases include modalities such as   radiotherapy, 
orthopedic surgery, bone-targeting pharmaceuticals, and antitumor therapy. 
  Zoledronic acid (ZA), marketed as Zometa® (Novartis, Basel, Switzerland), is 
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commonly   prescribed to delay SREs in patients with bone 
metastases. In a pivotal Phase III ZA clinical trial, decreased 
infusion time was found to be associated with decreased 
renal safety.5 Therefore, ZA is administered intravenously 
every 3 to 4 weeks6 over a minimum of 15 minutes to 
reduce the risk of clinically significant deterioration in 
renal function. ZA’s infusion time has been cited as an 
advantage over other bisphosphonates (eg, pamidronate),7,8 
which typically require 2 to 3 hours for infusion. In clinical 
practice, however, administration time for ZA is notably 
longer than the 15-minute minimum specified on the 
label. Additionally, due to the risk of renal toxicity, renal 
monitoring is recommended before each intravenous (IV) 
bisphosphonate infusion.9–11
Longer administration time associated with ZA and 
the potential need for a separate visit for serum creatinine 
testing for renal monitoring may add substantially to the 
burden to patients, caregivers, and healthcare providers. 
However, limited data have been published regarding the 
time burden associated with cancer care. A study assessing 
the time burden on patients receiving care for colorectal 
cancer estimated that patients spent, on average, 432 hours 
seeking medical services (such as office visits, emergency 
room visits, chemotherapy, radiation therapy, hospitaliza-
tion, and outpatient surgery) during their final 12 months 
of life.12 This estimate included time spent travelling to and 
from the clinic, waiting at the clinic, and receiving care. 
Additional burden associated with drug administration and 
visits to the clinic can add substantially to the already high 
disease burden associated with advanced cancer. In addi-
tion, cancer care can also significantly add to the caregivers’ 
burden.12 A study estimating time costs associated with 
informal caregiving for cancer survivors concluded that 
the amount of caregiver time spent was highest for patients 
with metastatic disease compared to patients with local or 
regional cancers.
A handful of time and motion studies on treatment of 
bone metastases have been published.7,8,13–15 One study was 
published in Italian,14 and another was available as an abstract 
only.15 A study in the UK at three hospitals reported that while 
intravenous (IV) ZA infusion, on average, took 18 minutes, 
patients spent an average of 98 minutes at the administration 
unit.13 The single peer reviewed manuscript from a US-based 
study reported data from three sites, each with two patients 
per site where only one patient received IV ZA. This small 
study estimated that administration time for ZA averaged 
66 minutes, of which 25 minutes was accounted for by infu-
sion time and the remaining 41 minutes by ancillary tasks.7 
The applicability of these studies to current clinical practice 
in the US is limited as they either included few patients, 
were conducted outside of the US, or were conducted prior 
to the inclusion of renal monitoring guidelines which rec-
ommend serum creatinine testing before IV bisphosphonate 
administration.
As the majority of patients with breast or prostate cancer 
and bone metastases do not receive ZA infusion and chemo-
therapy infusion on the same day, the primary objective of 
this analysis was to delineate the overall time associated with 
administration of IV ZA in patients with bone metastases 
secondary to breast or prostate cancer who did not receive 
chemotherapy on the same day. A secondary objective was 
to quantify the mean time spent by healthcare professionals 
in the preparation or administration of ZA.
Methods
This time and motion study was conducted at seven oncol-
ogy clinics in the US and measured time associated with 
administration of IV ZA in patients with bone metastasis 
secondary to breast or prostate cancer.
Eligibility criteria
Patients were eligible to be included in this study if they 
were 18 years of age or older, were able to read and write 
English, and had a confirmed diagnosis of bone metastasis 
secondary to breast or prostate cancer. Each patient was 
observed only once and subsequent visits by the same 
patient for ZA infusions were not included. In addition, 
patients who were participating in a clinical trial of an 
investigational new drug to treat bone metastasis were 
excluded from the study. Eligibility of the sites to par-
ticipate in this study was based on prior clinical research 
experience and availability of a study coordinator on site. 
In addition, sites were also required to be administering ZA 
to 25 to 50 patients per month to be considered eligible to 
participate in this study. In order to delineate the time burden 
specifically associated with ZA, patients who visited the 
clinic to receive IV ZA but were not scheduled to receive 
chemotherapy on the same day were identified. Data for 
patients who received chemotherapy in conjunction with 
ZA administration during the same infusion visit have been 
reported previously.16
Study protocol, informed consent, and all other study-
related materials were approved by institutional review 
boards at each participating site prior to the start of data 
collection. Written informed consent was obtained from all 
patients prior to enrollment.
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Observer training
Data were entered in the observer form by six trained 
observers. Observers were trained by observing and tim-
ing five mock videotaped sessions of ZA administration. 
Observer inter-rater reliability was assessed by calculating 
the intraclass correlation coefficient (ICC). All observers 
were required to obtain an ICC of at least 0.7 or greater to 
be qualified to observe patients in this study.16 In addition, 
interabstractor reliability was also evaluated by having two 
independent trained observers time the infusion activities for 
10% of the patients.
Data collection
Data were collected using an observer form, site ques-
tionnaire, and a case report form. The observer form was 
used to collect time and motion data associated with ZA 
  administration. This form collected total administration 
time for each task, as well as time spent by each healthcare 
provider during the administration of ZA. A site question-
naire was used to record details about each site, such as 
geographic location, number of staff, number of patient 
visits per day, staff experience, number of infusion chairs, 
third-party payer distribution, and site-specific variable and 
fixed costs. Case report forms were used to collect patient 
information such as demographics, medical history, comor-
bidities, renal function assessment (date and location), and 
concomitant medication use.
Time and motion data associated with individual activi-
ties such as preinfusion tasks (vital signs, blood draw, and 
physical exam), ZA preparation, infusion tasks (hydration 
and ZA infusion), and follow-up activities (eg, removal 
of IV access line, recording of blood pressure, assessment 
for adverse drug reactions, patient counseling, prescrib-
ing medications) were recorded by trained observers on 
the observer form using a calibrated stop watch. For tasks 
which occurred concurrently, the task that involved direct 
contact with the patient was preferentially recorded and, for 
tasks that could not be observed, time was assigned based 
on the shortest recorded time for other patients receiving 
such a task.
Statistical analysis
No formal hypotheses were tested. Descriptive summaries 
for all variables were provided, including mean, median, and 
standard deviation (SD) for continuous variables, and fre-
quency distribution and percentages for categorical variables. 
Data were tabulated in subgroups by cancer type (breast or 
prostate cancer).
Results
Clinic details
Data were collected from seven clinics in the US, with a 
mean clinic size of 10,086 square feet and approximately 
five examination rooms.16 On average, clinics were open 
for 39 hours per week and staffed with two full-time medi-
cal oncologists. Each clinic provided IV ZA treatment to an 
average of 42.4 patients per month and the mean treatment 
duration was 17.6 months. An ICC value of 0.94 for pre-study 
observer training and of .0.99 for dual abstractions by two 
independent abstractors was achieved in this study.16
Patient characteristics
A total of 68 patients were enrolled, 42 with breast cancer 
and 26 with prostate cancer. Data for 24 breast and 15 pros-
tate cancer patients who received ZA during their regularly 
scheduled office visit and did not receive chemotherapy are 
reported here.
Mean age for breast cancer patients was 60.6 (SD 12.6) 
years and for prostate cancer patients was 73.9 (SD 8.5) years. 
Breast cancer patients had been diagnosed with bone metas-
tases for a mean of 2.2 (SD 1.5) years and prostate cancer 
patients had been diagnosed for a mean of 2.0 (SD 2.7) 
years. Baseline demographic and clinical characteristics 
are summarized in Table 1 by cancer type. The most 
common comorbid conditions observed in this sample 
included musculoskeletal comorbidities (breast cancer: 
58%; prostate cancer: 40%), cardiovascular and respiratory 
comorbidities (breast cancer: 25%; prostate cancer: 73%), 
and endocrine-related comorbidities (breast cancer: 45%; 
prostate cancer: 27%).
Table 1 Demographic information by cancer type
Breast cancer  
(N = 24)
Prostate cancer  
(N = 15)
Total  
(N = 39)
Age (years)
Mean( SD) 60.6 (12.6) 73.9 (8.5) 65.7 (12.9)
65 n (%) 9 (37.5%) 13 (86.7%) 22 (56.4%)
Gender n (%)
Male 0 (0.0%) 15 (100.0%) 15 (38.5%)
Race/ethnicity n (%)
White or caucasian 21 (87.5%) 15 (100.0%) 36 (92.3%)
Hispanic or latino 3 (12.5%) 0 (0.0%) 3 (7.7%)
Years since cancer diagnosis
Mean (SD) 7.3 (5.1) 7.8 (6.8) 7.5 (5.7)
Years since onset of metastatic bone disease
Mean (SD) 2.2 (1.5) 2.0 (2.7) 2.1 (2.0)
Years from cancer diagnosis to onset of metastatic bone disease
Mean (SD) 5.1 (4.6) 5.8 (6.6) 5.4 (5.4)
Abbreviation: SD, standard deviation.
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Secondary to renal toxicity, the Zometa label specifies 
that renal function should be assessed prior to each infusion. 
Renal function was assessed for 63% of breast and 87% of 
prostate cancer patients prior to infusion. Table 2 summarizes 
patient renal assessment by cancer type.
Administration of ZA
Administration time by each activity and cancer type is 
summarized in Table 3. Mean ZA administration time was 
72.1(SD 47.1) minutes for breast cancer, 65.0 (SD 32.5) 
minutes for prostate cancer, and 69.4 (SD 41.8) minutes for 
both cancer groups combined. The median overall admin-
istration time for breast and prostate cancer combined was 
60 minutes. Mean ZA infusion time was 33.9 (SD 15.1) 
minutes for breast cancer, 29.4 (SD 12.1) minutes for 
prostate cancer, and 32.2 (SD 14) minutes for both cancers 
combined. Approximately 58% (n = 14) of breast cancer and 
60% (n = 9) of prostate cancer patients received hydration 
prior to ZA administration. Mean infusion time for hydration 
was 33.2 (SD 29.6) minutes for breast cancer, 36.6 (SD 26.4) 
minutes for prostate cancer, and 34.6 (SD 27.8) minutes for 
both cancers combined.
The mean time spent by healthcare providers for IV 
infusion of ZA was 16.4 (SD 21.0) minutes for registered 
nurses, 10.7 (SD 20.2) minutes for nurse practitioners, and 
8.1 (SD 6.5) minutes for physicians (Table 4). Pharmacists’ 
time was generally not captured as ZA preparation occurred 
simultaneously with other activities.
Discussion
ZA is administered to patients with bone metastasis 
  secondary to advanced cancer over a minimum of 15 minutes 
to reduce the risk of renal toxicity. This 15-minute minimum 
infusion time has been cited as an advantage of ZA over 
other bisphosphonates that require longer infusion time.13 
In clinical practice, however, overall administration time for 
ZA may be notably greater than the minimum 15 minutes 
recommended on the label, and has been found to average 
from 60 to 98 minutes,7,13 due to additional activities related 
to preinfusion, drug preparation, drug infusion, and follow-
up. This extended administration time can burden patients, 
healthcare personnel, and hospital or clinic resources.
Unlike previous studies that were conducted during 
clinical trials and/or included few patients,7,8 this time and 
motion study was conducted when patients made regularly 
scheduled clinic visits to receive IV ZA, and recruited a much 
larger patient group for both breast and prostate cancer. As 
the patients in this analysis were not scheduled to receive 
concomitant chemotherapy, the time estimates reported here 
are directly attributable to ZA administration. Research has 
shown that majority of patients receiving ZA do not receive 
chemotherapy on the same day, with a US claims database 
analysis demonstrating that only 30% of patients receive both 
ZA and chemotherapy on the same day. Consequently, time 
and motion results for patients receiving IV ZA without same-
day chemotherapy administration are relevant to the majority 
Table 3 Administration time by cancer type
Activity/task Breast cancer (N = 24) Prostate cancer (N = 15) Total (N = 39)
n (%) Mean (SD)  
Time, minutes
n (%) Mean (SD)  
Time, minutes
n (%) Mean (SD)  
Time, minutes
Pre-infusion 24 (100.0) 12.5 (24.8) 15 (100.0) 10.6 (7.4) 39 (100.0) 11.8 (19.8)
Vital signs 24 (100.0) 6.6 (21.5) 13 (100.0) 2.0 (0.8) 37 (94.8) 5.0 (17.4)
Blood draw 12 (50.0) 2.2 (1.2) 8 (53.0) 4.0 (3.4) 20 (51.2) 2.9 (2.4)
Physical exam 13 (54.0) 8.9 (7.5) 10 (66.0) 10.1 (6.1) 23 (58.9) 9.4 (6.8)
Zoledronic acid preparation 24 (100) 2.1 (1.1) 15 (100.0) 1.6 (1.1) 39 (100.0) 1.9 (1.1)
Infusion 24 (100) 55.4 (31.4) 15 (100.0) 51.4 (30.9) 39 (100.0) 53.9 (30.8)
  Hydration 14 (58.0) 33.2 (29.6) 9 (60.0) 36.6 (26.4) 23 (58.9) 34.6 (27.8)
  Zoledronic acid 24 (100.0) 33.9 (15.1) 15 (100.0) 29.4 (12.1) 39 (100.0) 32.2 (14.0)
Follow-up 24 (57.1) 2.0 (1.5) 15 (57.7) 1.4 (0.6) 39 (57.4) 1.8 (1.2)
Total 24 (57.1) 72.1 (47.1) 15 (57.7) 65.0 (32.5) 39 (57.4) 69.4 (41.8)
Abbreviation: SD, standard deviation.
Table 2 Renal assessment
Breast cancer  
(N = 24)
Prostate cancer  
(N = 15)
Total  
(N = 39)
Renal function  
assessed n (%)
15 (62.5%) 13 (86.7%) 28 (71.8%)
Assessments done  
during a separate  
visita,* n (%)
6 (40%) 5 (38.4%) 11 (39.2%)
On-site laboratory  
assessment of those  
whose renal function  
was assessed) n (%)
9 (60%) 8 (61.5%) 17 (60.7%)
Note: a,*Of those whose renal function was assessed.
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of patients with bone metastases who are treated with IV ZA. 
This study was conducted at multiple sites and can therefore 
be considered more representative of clinical practice in the 
US compared to previous studies. The observers employed 
for data collection were rigorously trained to ensure high data 
quality. Therefore, the time and motion methodology used in 
this study was more robust compared with previous studies.
Results from this study confirmed that ZA infusion 
combined with ancillary tasks associated with IV infusions 
resulted in a total administration time that was much longer 
(mean 69.4 minutes; median 60 minutes) than the minimum 
infusion time stated in the Zometa label. Further break down 
of time by activity found that on average, ZA infusion alone 
took 32.2 minutes, which is more than twice the minimum 
15-minute infusion time recommended. In addition, as ZA 
and other bisphosphonates are risk factors for subsequent 
renal deterioration, hydration therapy is required for all 
patients receiving ZA. This study found that administration 
of hydration therapy significantly prolonged ZA administra-
tion time. Additionally, this study found that longer infusion 
time for IV ZA also required substantial time commitment per 
patient from multiple healthcare personnel (such as registered 
nurses, nurse practitioners, and physicians).
A limitation of this study is that only direct time data in 
the clinic were collected, so indirect time burden on patients 
in terms of lost work time or time for travel were not captured. 
Also, many patients made separate visits to the laboratory 
for serum creatinine testing and this additional time was not 
quantified in this study. Therefore, the overall time burden 
to patients and their caregivers is expected to be greater than 
that estimated in this study. Additionally, time for tasks that 
occurred simultaneously was not recorded separately, and 
could potentially lead to under-reporting of the time bur-
den on healthcare professionals. In addition, as healthcare 
personnel administering IV ZA were aware that they were 
being observed and timed in relation to activities associated 
with ZA infusion, they may have demonstrated increased 
efficiency in their activities (ie, Hawthorne effect).17 Lastly, 
only sites that were administering ZA to 25 to 50 patients 
per month and had prior clinical research experience were 
eligible to participate in this study. Therefore, the results 
reported here may be generalized only to similar practices.
Conclusion
This time and motion study quantified the overall time required 
for IV ZA administration for patients with bone metastasis 
secondary to breast or prostate cancers, who received IV ZA 
infusion during a regularly scheduled infusion clinic visit. 
Overall, it was found that the mean time for ZA infusion, 
including hydration, was much higher than the minimum infu-
sion time specified in the Zometa package insert. In addition 
to longer administration time, ZA infusion was also associated 
with a substantial time burden for healthcare providers. The 
results of this study demonstrate the need for more efficient 
therapeutic agents to decrease the burden associated with 
cancer care in patients with bone metastasis.
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